MYMD PHARMACEUTICALS INC (MYMD) Fundamental Analysis & Valuation

NASDAQ:MYMD • US62856X2018

Current stock price

1.82 USD
0 (0%)
Last:

This MYMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MYMD Profitability Analysis

1.1 Basic Checks

  • MYMD had negative earnings in the past year.
  • In the past year MYMD has reported a negative cash flow from operations.
MYMD Yearly Net Income VS EBIT VS OCF VS FCFMYMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of MYMD (-32.43%) is comparable to the rest of the industry.
  • MYMD has a Return On Equity (-43.95%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -32.43%
ROE -43.95%
ROIC N/A
ROA(3y)-84.95%
ROA(5y)-85.91%
ROE(3y)-93.54%
ROE(5y)-101.66%
ROIC(3y)N/A
ROIC(5y)N/A
MYMD Yearly ROA, ROE, ROICMYMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MYMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MYMD Yearly Profit, Operating, Gross MarginsMYMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MYMD Health Analysis

2.1 Basic Checks

  • MYMD has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for MYMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MYMD Yearly Shares OutstandingMYMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
MYMD Yearly Total Debt VS Total AssetsMYMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of -7.99, we must say that MYMD is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of MYMD (-7.99) is worse than 73.20% of its industry peers.
  • There is no outstanding debt for MYMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.99
ROIC/WACCN/A
WACCN/A
MYMD Yearly LT Debt VS Equity VS FCFMYMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 1.71 indicates that MYMD should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.71, MYMD is not doing good in the industry: 71.65% of the companies in the same industry are doing better.
  • MYMD has a Quick Ratio of 1.71. This is a normal value and indicates that MYMD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.71, MYMD is doing worse than 67.53% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
MYMD Yearly Current Assets VS Current LiabilitesMYMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. MYMD Growth Analysis

3.1 Past

  • MYMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.63%, which is quite impressive.
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MYMD Yearly Revenue VS EstimatesMYMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 1M 2M 3M 4M 5M
MYMD Yearly EPS VS EstimatesMYMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 -5K -10K

More info and screens

Find the best growth stocksShow best growing peers

0

4. MYMD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MYMD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYMD Price Earnings VS Forward Price EarningsMYMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYMD Per share dataMYMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MYMD Dividend Analysis

5.1 Amount

  • No dividends for MYMD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

MYMD Fundamentals: All Metrics, Ratios and Statistics

MYMD PHARMACEUTICALS INC

NASDAQ:MYMD (7/23/2024, 8:26:03 PM)

1.82

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13
Earnings (Next)08-12
Inst Owners2.93%
Inst Owner Change-37.14%
Ins Owners88.61%
Ins Owner Change0%
Market Cap4.20M
Revenue(TTM)N/A
Net Income(TTM)-7.08M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.76
FCFYN/A
OCF(TTM)-5.76
OCFYN/A
SpS0
BVpS6.97
TBVpS2.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.43%
ROE -43.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.95%
ROA(5y)-85.91%
ROE(3y)-93.54%
ROE(5y)-101.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z -7.99
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.2%
OCF growth 3YN/A
OCF growth 5YN/A

MYMD PHARMACEUTICALS INC / MYMD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MYMD PHARMACEUTICALS INC (MYMD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYMD.


What is the valuation status for MYMD stock?

ChartMill assigns a valuation rating of 0 / 10 to MYMD PHARMACEUTICALS INC (MYMD). This can be considered as Overvalued.


How profitable is MYMD PHARMACEUTICALS INC (MYMD) stock?

MYMD PHARMACEUTICALS INC (MYMD) has a profitability rating of 1 / 10.


How sustainable is the dividend of MYMD PHARMACEUTICALS INC (MYMD) stock?

The dividend rating of MYMD PHARMACEUTICALS INC (MYMD) is 0 / 10 and the dividend payout ratio is 0%.